Annexin Pharmaceuticals AB (ANNX) - Net Assets
Based on the latest financial reports, Annexin Pharmaceuticals AB (ANNX) has net assets worth Skr24.93 Million SEK (≈ $2.68 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr30.16 Million ≈ $3.25 Million USD) and total liabilities (Skr5.22 Million ≈ $562.19K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Annexin Pharmaceuticals AB total liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr24.93 Million |
| % of Total Assets | 82.68% |
| Annual Growth Rate | 22.35% |
| 5-Year Change | -46.64% |
| 10-Year Change | 60.09% |
| Growth Volatility | 73.49 |
Annexin Pharmaceuticals AB - Net Assets Trend (2014–2025)
This chart illustrates how Annexin Pharmaceuticals AB's net assets have evolved over time, based on quarterly financial data. Also explore ANNX current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Annexin Pharmaceuticals AB (2014–2025)
The table below shows the annual net assets of Annexin Pharmaceuticals AB from 2014 to 2025. For live valuation and market cap data, see Annexin Pharmaceuticals AB stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr24.93 Million ≈ $2.68 Million |
+81.81% |
| 2024-12-31 | Skr13.71 Million ≈ $1.48 Million |
-27.11% |
| 2023-12-31 | Skr18.81 Million ≈ $2.02 Million |
-37.60% |
| 2022-12-31 | Skr30.15 Million ≈ $3.24 Million |
-35.47% |
| 2021-12-31 | Skr46.73 Million ≈ $5.03 Million |
+126.41% |
| 2020-12-31 | Skr20.64 Million ≈ $2.22 Million |
+79.63% |
| 2019-12-31 | Skr11.49 Million ≈ $1.24 Million |
-71.17% |
| 2018-12-31 | Skr39.85 Million ≈ $4.29 Million |
+63.05% |
| 2017-12-31 | Skr24.44 Million ≈ $2.63 Million |
+56.93% |
| 2016-12-31 | Skr15.57 Million ≈ $1.68 Million |
+11467.88% |
| 2015-12-31 | Skr-137.00K ≈ $-14.74K |
-105.06% |
| 2014-12-31 | Skr2.71 Million ≈ $291.57K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Annexin Pharmaceuticals AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 37208461700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr11.68 Million | 46.86% |
| Other Components | Skr386.61 Million | 1550.64% |
| Total Equity | Skr24.93 Million | 100.00% |
Annexin Pharmaceuticals AB Competitors by Market Cap
The table below lists competitors of Annexin Pharmaceuticals AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Delixy Holdings Limited Ordinary Shares
NASDAQ:DLXY
|
$11.24 Million |
|
Energoinstal S.A.
WAR:ENI
|
$11.25 Million |
|
Dycasa SA
BA:DYCA
|
$11.25 Million |
|
eEducation Albert AB
ST:ALBERT
|
$11.25 Million |
|
Max Resource Corp
V:MAX
|
$11.24 Million |
|
Sirona Biochem Corp
V:SBM
|
$11.23 Million |
|
Biovie Inc
NASDAQ:BIVI
|
$11.23 Million |
|
Calibre
PA:ALWIN
|
$11.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Annexin Pharmaceuticals AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 13,713,000 to 24,932,000, a change of 11,219,000 (81.8%).
- Net loss of 36,893,000 reduced equity.
- Share repurchases of 49,973,000 reduced equity.
- New share issuances of 49,973,000 increased equity.
- Other factors increased equity by 48,112,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-36.89 Million | -147.97% |
| Share Repurchases | Skr49.97 Million | -200.44% |
| Share Issuances | Skr49.97 Million | +200.44% |
| Other Changes | Skr48.11 Million | +192.97% |
| Total Change | Skr- | 81.81% |
Book Value vs Market Value Analysis
This analysis compares Annexin Pharmaceuticals AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.93x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | Skr-0.02 | Skr14.80 | x |
| 2016-12-31 | Skr1.78 | Skr14.80 | x |
| 2017-12-31 | Skr2.92 | Skr14.80 | x |
| 2018-12-31 | Skr1.89 | Skr14.80 | x |
| 2019-12-31 | Skr0.23 | Skr14.80 | x |
| 2020-12-31 | Skr0.18 | Skr14.80 | x |
| 2021-12-31 | Skr0.35 | Skr14.80 | x |
| 2022-12-31 | Skr0.12 | Skr14.80 | x |
| 2023-12-31 | Skr0.11 | Skr14.80 | x |
| 2024-12-31 | Skr0.03 | Skr14.80 | x |
| 2025-12-31 | Skr3.77 | Skr14.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Annexin Pharmaceuticals AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -147.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.21x
- Recent ROE (-147.97%) is below the historical average (-147.70%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -51.19% | 0.00% | 0.00x | 1.36x | Skr-1.66 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | Skr-5.02 Million |
| 2016 | -63.12% | 0.00% | 0.00x | 1.51x | Skr-11.39 Million |
| 2017 | -126.55% | 0.00% | 0.00x | 1.26x | Skr-33.37 Million |
| 2018 | -72.39% | 0.00% | 0.00x | 1.16x | Skr-32.83 Million |
| 2019 | -247.16% | 0.00% | 0.00x | 1.40x | Skr-29.54 Million |
| 2020 | -216.80% | 0.00% | 0.00x | 1.22x | Skr-46.81 Million |
| 2021 | -111.59% | 0.00% | 0.00x | 1.13x | Skr-56.81 Million |
| 2022 | -135.06% | 0.00% | 0.00x | 1.22x | Skr-43.74 Million |
| 2023 | -234.16% | 0.00% | 0.00x | 1.42x | Skr-45.94 Million |
| 2024 | -366.46% | 0.00% | 0.00x | 1.39x | Skr-51.62 Million |
| 2025 | -147.97% | 0.00% | 0.00x | 1.21x | Skr-39.39 Million |
Industry Comparison
This section compares Annexin Pharmaceuticals AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $181,303,105
- Average return on equity (ROE) among peers: -64.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Annexin Pharmaceuticals AB (ANNX) | Skr24.93 Million | -51.19% | 0.21x | $11.24 Million |
| 2cureX AB (2CUREX) | $74.34 Million | -25.47% | 0.06x | $4.90 Million |
| Ascelia Pharma AB (publ) (ACE) | $74.33 Million | -147.03% | 0.17x | $40.96 Million |
| AcouSort AB (ACOU) | $15.58 Million | -57.51% | 0.12x | $8.97 Million |
| Active Biotech AB (ACTI) | $188.64 Million | -118.73% | 1.64x | $17.19 Million |
| Alzinova AB (ALZ) | $20.63 Million | -16.51% | 0.08x | $4.97 Million |
| AlzeCure Pharma (ALZCUR) | $182.01 Million | -28.02% | 0.03x | $18.18 Million |
| Alligator Bioscience AB (ATORX) | $68.52 Million | -112.06% | 0.43x | $14.33 Million |
| BioInvent International AB (BINV) | $219.00 Million | -63.86% | 0.22x | $155.44 Million |
| BioArctic AB (publ) (BIOA-B) | $788.68 Million | -15.19% | 0.14x | $2.59 Billion |
About Annexin Pharmaceuticals AB
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and … Read more